Stroke Medical, a China-based medical device developer backed by conglomerate Fosun, has closed almost RMB100m ($14.1m) in funding, in a round led by investment firm Hidea Venture Capital.
Shengyu Investment and Grand Yangtze Capital also contributed to the round, which followed an undisclosed amount of series A funding from Fosun’s healthcare affiliate, Fosun Pharma, in November 2018 according to China Money Network.
Founded in 2016, Stroke Medical is working on minimally invasive devices that are intended to prevent and treat strokes, and to help in post-stroke rehabilitation.
The company’s technology includes a system designed to prevent strokes by treating stenosis, a build-up of plaque in a patient’s arteries that restricts the transfer of blood to the brain. The cash will be used to support clinical trials for its devices.
